Last reviewed · How we verify
Fespixon cream
Fespixon cream is a Small molecule drug developed by National Defense Medical Center, Taiwan. It is currently FDA-approved for Wound healing and tissue repair (specific indications not clearly documented in available sources). Also known as: ON101 cream, ON101 Cream.
Fespixon is a topical cream formulation designed to promote wound healing and tissue repair through anti-inflammatory and antimicrobial properties.
Fespixon is a topical cream formulation designed to promote wound healing and tissue repair through anti-inflammatory and antimicrobial properties. Used for Wound healing and tissue repair (specific indications not clearly documented in available sources).
At a glance
| Generic name | Fespixon cream |
|---|---|
| Also known as | ON101 cream, ON101 Cream |
| Sponsor | National Defense Medical Center, Taiwan |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Fespixon cream is a marketed topical formulation developed for dermatological use, likely containing active ingredients that support wound healing processes. The exact molecular mechanism is not well-documented in widely available literature, but topical formulations of this type typically work through reducing inflammation, preventing infection, and promoting epithelialization of damaged skin.
Approved indications
- Wound healing and tissue repair (specific indications not clearly documented in available sources)
Common side effects
Key clinical trials
- A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers. (PHASE4)
- Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B) (PHASE4)
- Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound (PHASE4)
- Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients (PHASE4)
- Explore the Short- and Mid-term Effects of Fespixon in Scar Cosmesis Following Cervical or Abdominal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fespixon cream CI brief — competitive landscape report
- Fespixon cream updates RSS · CI watch RSS
- National Defense Medical Center, Taiwan portfolio CI
Frequently asked questions about Fespixon cream
What is Fespixon cream?
How does Fespixon cream work?
What is Fespixon cream used for?
Who makes Fespixon cream?
Is Fespixon cream also known as anything else?
What development phase is Fespixon cream in?
Related
- Manufacturer: National Defense Medical Center, Taiwan — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Wound healing and tissue repair (specific indications not clearly documented in available sources)
- Also known as: ON101 cream, ON101 Cream
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing